Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites
Evaluate a multi-faceted training program to improve short-term smoking cessation rates (\<14 days post-visit) and short (3 months) and sustained abstinence (6 months) among 1,114 enrolled smokers who present for low-dose computed tomography (LDCT) lung cancer screening in 26 community-based practices.
Checked against the public recordLast updated Jul 25, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Health Services Research
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Wake Forest University Health Sciences
- Interventions being studied
- Other: Personnel Training and Coaching Calls
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Agrees to have NCORP research personnel serve as the study liaison and another person to serve as the cessation program champion. * Agrees to participate in all aspects of the intervention, randomization, and evaluation. * Agrees to participate in a confidential 1-on-1 semi-structured interview with the research team. * Agrees to have the interview taped, transcribed and qualitatively analyzed. * Age ≥18 years * Potential participants will be screened using the following question: "Do you smoke cigarettes every day, some days, or not at all?" (BRFSS). A current smoker is anyone responds "every day" or "some days". Exclusion Criteria: * Current use (previous 30 days) of a tobacco dependence treatment including bupropion, varenicline, and nicotine replacement * Individuals who use e-cigarettes and who are not smoking cigarettes. Dual users (those who use both e-cigarettes and cigarettes) will still be included in the trial. * The presence of a physical or cognitive impairment that would prevent a person from engaging in survey research (such as blindness, deafness, or dementia). * Individual has already completed the intended LDCT lung cancer screening for this study. * Non-English speaking participants.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Helen F Graham Cancer CenterNewark, Delaware
- Augusta University Medical CenterAugusta, Georgia
- Lewis Cancer and Research Pavilion at Saint Joseph's/CandlerSavannah, Georgia
- Tripler Army Medical CenterHonolulu, Hawaii
- Good Samaritan Regional Health CenterMount Vernon, Illinois
- Carle Cancer CenterUrbana, Illinois
- McFarland Clinic PC - AmesAmes, Iowa
- Mercy Medical Center - Des MoinesDes Moines, Iowa
- LSU Health Sciences Center at ShreveportShreveport, Louisiana
- Saint Joseph Mercy HospitalAnn Arbor, Michigan
- Spectrum Health at Butterworth CampusGrand Rapids, Michigan
- William Beaumont Hospital-Royal OakRoyal Oak, Michigan
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 25, 2022. Always confirm current availability with the study team.